米力农及左西孟旦应用于慢性心衰急性发作治疗中的效果对比  

Comparison of effect between milrinone and levosimendan applied in the treatment of acute exacerbation of chronic heart failure

作　　者：曹军[1] 

机构地区：[1]河南省新乡市中心医院急诊科,453000

出　　处：《中国实用医药》2016年第22期12-13,共2页China Practical Medicine

摘　　要：目的研究米力农以及左西孟旦应用于慢性心力衰竭(心衰)急性发作患者临床治疗中的作用。方法 164例慢性心衰急性发作患者,根据给予药物不同分为米力农组及左西孟旦组,每组82例。米力农组接受米力农治疗,左西孟旦组接受左西孟旦治疗。观察两组的临床治疗效果。结果治疗后左西孟旦组N末端脑钠肽前体(NT-pro BNP)(447.0±150.0)pg/ml、去甲肾上腺素(NE)(378.5±27.5)pg/ml、左室射血分数(LVEF)(48.05±3.90)%均优于米力农组(675.0±195.0)pg/ml、(407.4±45.3)pg/ml、(43.69±5.71)%(P<0.05)。结论针对慢性心衰急性发作患者,选择左西孟旦进行治疗更有利于改善患者心室收缩功能,同时能够针对患者心室重构进行延缓。Objective To research effects by milrinone and levosimendan applied in the clinical treatment of acute exacerbation of chronic heart failure. Methods A total of 164 patients with acute exacerbation of chronic heart failure were divided by different medication into milrinone group and levosimendan group, with 82 cases in each group. The milrinone group received milrinone, and the levosimendan group received levosimendan for treatment. Clinical effects of both groups were observed. Results After treatment, the levosimendan group had all better N-terminal pro-brain natriuretic peptide（NT-pro BNP） as（447.0±150.0） pg/ml, noradrenaline（NE） as（378.5±27.5） pg/ml and left ventricular ejection fraction（LVEF） as（48.05±3.90） % than（675.0±195.0） pg/ml,（407.4±45.3） pg/ml and（43.69±5.71） % in the milrinone group（P〈0.05）. Conclusion Implement of levosimendan for patients with acute exacerbation of chronic heart failure is helpful to improve ventricular systolic function and suspend ventricular remodeling.

关 键 词：米力农 左西孟旦 慢性心力衰竭急性发作 

分 类 号：R541.6[医药卫生—心血管疾病]